Kazuo Mihara

The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients

Akihito Suzuki, Kazuo Mihara, Tsuyoshi Kondo et al. · Pharmacogenetics · 2000 · 101 citations

Medicine, Pharmacology, Psychiatry +17

Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

Magnus Christensen, Gunnel Tybring, Kazuo Mihara et al. · Clinical Pharmacology & Therapeutics · 2002 · 91 citations

Medicine, Pharmacokinetics, Pharmacology +16

Association of the <i>Taq</i>I A Polymorphism of the Dopamine D₂ Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome

Akihito Suzuki, Tsuyoshi Kondo, K. Otani et al. · American Journal of Psychiatry · 2001 · 80 citations

Life Sciences, Genetics, Psychiatry +12

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

Akihito Suzuki, Koichi Otani, Kazuo Mihara et al. · Pharmacogenetics · 1997 · 69 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +17

The –141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients

Akihito Suzuki, Tsuyoshi Kondo, Kazuo Mihara et al. · Pharmacogenetics · 2001 · 68 citations

Medicine, Genetics, Psychiatry +17